Program
Pioglitazone
Also written as “pioglitazone”, “Pioglitazone 30 mg” and “Pioglitazone and azilsartan”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Alzheimer Disease · Fatty Liver · Peripheral Arterial Disease, led by 10 companies.
Drug pagePioglitazone: every studyMany companies study it; this page follows only the 52 they lead. All 336 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takedaits history only | 330 open or running | phase 4since Jun 27, 2007 | Sep 9, 2005 | none ahead |
| Boryung Pharmaceuticalits history only | 42 open or running | phase 3since May 9, 2021 | May 9, 2021 | none ahead |
| Merckits history only | 40 open or running | phase 3since Jul 22, 2008 | Aug 2, 2007 | none ahead |
| GlaxoSmithKlineits history only | 30 open or running | phase 4since Apr 2, 2009 | Dec 22, 2005 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 4since Oct 16, 2007 | Oct 16, 2007 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Dr. Muhammad Abdulghaniits history only | 10 open or running | no phasesince Aug 16, 2016 | Aug 16, 2016 | none ahead |
| Getz Pharmaits history only | 10 open or running | phase 4since Jul 19, 2021 | Jul 19, 2021 | none ahead |
| Medtronicits history only | 10 open or running | early phase 1since Jul 21, 2008 | Jul 21, 2008 | none ahead |
| Strekinits history only | 10 open or running | phase 3since Nov 1, 2017 | Nov 1, 2017 | none ahead |
Also a collaborator on its studies: Parexel, Zinfandel Pharmaceuticals, Eli Lilly and Takeda Pharmaceuticals North America.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 37 studies since Sep 9, 2005.
- Feb 1, 2011Phase 3 study in Diabetes Mellitus, Type 2Takeda · NCT01289119 · 506 enrolled · China, Hong Kong, Taiwan
- Sep 7, 2011Phase 1 study in Non-alcoholic Fatty Liver DiseaseMerck · NCT01431521 · 31 enrolled
- Oct 18, 2011Phase 1 study in HealthyTakeda · NCT01456117 · 61 enrolled · United States
- Aug 31, 2012Phase 4 study in Diabetes MellitusTakeda · NCT01686711 · 207 enrolled · Japan
- Aug 26, 2013Phase 3 study in Mild Cognitive Impairment Due to Alzheimer's DiseaseTakeda · NCT01931566 · 3,494 enrolled · United States, Australia, Germany and more
- Oct 24, 2013Phase 4 study in Diabetes Mellitus, Type 2Takeda · NCT01972724 · 114 enrolled · Korea, Republic of
- Nov 4, 2014Phase 3 study in Mild Cognitive Impairment Due to Alzheimer's DiseaseTakeda · NCT02284906 · 40 enrolled · United States, Australia, Switzerland and more
- Feb 19, 2015Phase 1 study in AnemiaGlaxoSmithKline · NCT02371603 · 70 enrolled · United States
- Aug 16, 2016Dr. Muhammad Abdulghani’s first study: no phase study in Diabetes Mellitus, Type 2New to Dr. Muhammad AbdulghaniDr. Muhammad Abdulghani · NCT02887625 · 410 enrolled · Qatar
- Nov 1, 2017Strekin’s first study: phase 3 study in Acute Hearing LossNew to StrekinStrekin · NCT03331627 · 165 enrolled · Czechia, Germany, Switzerland
- May 9, 2021Boryung Pharmaceutical’s first study: phase 3 study in Type2 DiabetesNew to Boryung PharmaceuticalBoryung Pharmaceutical · NCT04885712 · 378 enrolled · Korea, Republic of
- Jul 19, 2021Getz Pharma’s first study: phase 4 study in Diabetes Mellitus, Type 2New to Getz PharmaGetz Pharma · NCT04976283 · 123 enrolled · Pakistan
- May 26, 2022Phase 1 study in Diabetes Mellitus, Type 2Boryung Pharmaceutical · NCT05411965 · 48 enrolled · Korea, Republic of
- Jul 16, 20252 phase 1 studies in Diabetes MellitusBoryung Pharmaceutical · NCT07083401, NCT07083388
TargetBeta
“Peroxisome proliferator-activated receptor gamma agonist”ChEMBL 37, by rule
Other programs on PPARG
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| saroglitazarrule | Zydus Lifesciences | phase 4 | 19 |
| chiglitazarrule | Chipscreen Biosciences | phase 3 | 9 |
| lanifibranor | inventiva-pharma | phase 3 | 6 |
| T3D-959rule | t3d-therapeutics-inc | phase 3 | 3 |
Studies
All 52 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07083401Diabetes Mellitus · South Korea | 1 | Recruiting | Boryung Pharmaceutical | Jul 5, 2026 | 40 |
| NCT07083388Diabetes Mellitus · South Korea | 1 | Recruiting | Boryung Pharmaceutical | Jul 3, 2026 | 52 |
| NCT05411965Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Boryung Pharmaceutical | Jul 3, 2022 | 48 |
| NCT04976283Diabetes Mellitus, Type 2 · Pakistan | 4 | UNKNOWN | Getz Pharma | May 15, 2023 | 123 |
| NCT04885712Type2 Diabetes · Korea, Republic of | 3 | Completed | Boryung Pharmaceutical | Sep 19, 2022 | 378 |
| NCT03331627Acute Hearing Loss · Czechia, Germany, Switzerland | 3 | Completed | Strekin | Feb 6, 2020 | 165 |
| NCT02887625Diabetes Mellitus, Type 2 · Qatar | – | UNKNOWN | Dr. Muhammad Abdulghani | May 2017 | 410 |
| NCT02371603Anemia · United States | 1 | Completed | GlaxoSmithKline | Aug 12, 2015 | 70 |
| NCT02284906Mild Cognitive Impairment Due to Alzheimer's Disease · United States, Australia, Switzerland and more | 3 | Terminated | Takeda | Jan 31, 2018 | 40 |
| NCT01972724Diabetes Mellitus, Type 2 · Korea, Republic of | 4 | Completed | Takeda | Oct 17, 2016 | 114 |
| NCT01931566Mild Cognitive Impairment Due to Alzheimer's Disease · United States, Australia, Germany and more | 3 | Terminated | Takeda | Jul 24, 2018 | 3,494 |
| NCT01686711Diabetes Mellitus · Japan | 4 | Completed | Takeda | Dec 2013 | 207 |
| NCT01456117Healthy · United States | 1 | Completed | Takeda | Jul 2012 | 61 |
| NCT01431521Non-alcoholic Fatty Liver Disease | 1 | Completed | Merck | Sep 18, 2012 | 31 |
| NCT01289119Diabetes Mellitus, Type 2 · China, Hong Kong, Taiwan | 3 | Completed | Takeda | Dec 2011 | 506 |
| NCT01124656Diabetes Mellitus, Type 2 | 3 | Terminated | Takeda | May 2007 | 26 |
| NCT01115712Overweight | 1 | Completed | Merck | Sep 2010 | 35 |
| NCT00879970Diabetes Mellitus, Type 2 · United States, Argentina, Canada and more | 4 | Terminated | GlaxoSmithKline | Nov 2010 | 1,332 |
| NCT00771004Coronary Artery Disease · Germany | 2 | Completed | Takeda | Feb 2009 | 63 |
| NCT00770952Diabetes Mellitus · Germany | 3 | Completed | Takeda | Dec 2008 | 91 |
| NCT00770653Diabetes Mellitus · Germany | 3 | Completed | Takeda | May 2009 | 305 |
| NCT00770640Diabetes Mellitus · Germany | 2 | Completed | Takeda | Jun 2010 | 40 |
| NCT00770575Cardiovascular Diseases | 2 | Completed | Takeda | Oct 2006 | 148 |
| NCT00770497Inflammation · Germany | 2 | Completed | Takeda | May 2008 | 172 |
| NCT00770445Diabetes Mellitus · Germany | 4 | Completed | Takeda | Jul 2010 | 121 |
| NCT00772174Diabetes Mellitus | 3 | Completed | Takeda | Feb 2008 | 418 |
| NCT00770835Diabetes Mellitus · Italy | 4 | Completed | Takeda | May 2011 | 39 |
| NCT00762736Diabetes Mellitus · United States, Argentina, Chile and more | 2 | Completed | Takeda | Oct 2005 | 704 |
| NCT00754403Diabetes Mellitus | 4 | Completed | Takeda | Oct 2006 | 312 |
| NCT00744367Diabetes Mellitus, Type 2 · United States, Brazil, Canada and more | 3 | Completed | Hoffmann-La Roche | Nov 2010 | 326 |
| NCT00727857Diabetes Mellitus · United States, Chile, Mexico and more | 3 | Completed | Takeda | Aug 2008 | 600 |
| NCT00722917Diabetes Mellitus · United States | 2 | Terminated | Takeda | Apr 2009 | 323 |
| NCT00722371Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Oct 26, 2010 | 1,615 |
| NCT00720577Peripheral Arterial Disease | Early 1 | Completed | Medtronic | Jul 2007 | 164 |
| NCT00708175Glucose Metabolism Disorders · United States | 4 | Completed | Takeda | Jan 2011 | 156 |
| NCT00676260Diabetes Mellitus · United Kingdom | 2 | Completed | Takeda | Aug 2004 | 29 |
| NCT00672919Diabetes Mellitus · United States, Puerto Rico | 4 | Completed | Takeda | Aug 2004 | 305 |
| NCT00649558Healthy · United States | 1 | Completed | Viatris | Mar 2003 | 36 |
| NCT00649012Healthy · United States | 1 | Completed | Viatris | Mar 2003 | 40 |
| NCT00545233Hepatitis C, Chronic · United States, Puerto Rico | 4 | Completed | Hoffmann-La Roche | Dec 2010 | 155 |
| NCT00521820Diabetes Mellitus | 3 | Terminated | Takeda | Oct 2003 | 518 |
| NCT00521742Diabetes Mellitus | 3 | Completed | Takeda | Jan 2003 | 300 |
| NCT00511108Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Feb 24, 2009 | 211 |
| NCT00494312Diabetes Mellitus | 4 | Completed | Takeda | Jun 2005 | 2,120 |
| NCT00395512Diabetes Mellitus · United States, Argentina, Australia and more | 3 | Completed | Takeda | Feb 2008 | 655 |
| NCT00376181Diabetes Mellitus, Type 2 · United States, Argentina, Chile and more | 3 | Terminated | Takeda | May 2007 | 96 |
| NCT00331487Diabetes Mellitus · United States | 3 | Completed | Takeda | Mar 2004 | 719 |
| NCT00328627Diabetes Mellitus, Type 2 · United States, Australia, Brazil and more | 3 | Completed | Takeda | Mar 2008 | 1,554 |
| NCT00269061Diabetes Mellitus, Type 2 · United States | 1 | Completed | GlaxoSmithKline | 32 | |
| NCT00225277Diabetes Mellitus · United States, Argentina, Canada and more | 3 | Completed | Takeda | Oct 2007 | 547 |
| NCT00225264Diabetes Mellitus · United States | 3 | Completed | Takeda | May 2006 | 458 |
| NCT00174993Diabetes Mellitus · Austria, Belgium, Czech Republic and more | 3 | Completed | Takeda | Jan 2005 | 4,373 |
How it is read
Names in the registry
- “Pioglitazone”, 33 entries
- “pioglitazone”, 5 entries
- “Pioglitazone 30 mg”, 4 entries
- “Pioglitazone and azilsartan”, 4 entries
- “TAK-379”, 3 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 42 studies
- Diabetes Mellitus, 4 studies
- Alzheimer Disease, 2 studies
- Fatty Liver, 1 study
- Peripheral Arterial Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.